Atnaujinkite slapukų nuostatas

El. knyga: Practical Pharmacology for Alzheimer's Disease

, , ,
  • Formatas: PDF+DRM
  • Išleidimo metai: 10-Feb-2016
  • Leidėjas: Springer International Publishing AG
  • Kalba: eng
  • ISBN-13: 9783319262062
Kitos knygos pagal šią temą:
Practical Pharmacology for Alzheimer's DiseaseDidesnis paveikslėlis
  • Formatas: PDF+DRM
  • Išleidimo metai: 10-Feb-2016
  • Leidėjas: Springer International Publishing AG
  • Kalba: eng
  • ISBN-13: 9783319262062
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

In this book, the four leading experts on the ACE inhibitors donepezil, galantamine, and rivastigmine and the NMDA receptor antagonist memantine explain the practical pharmacology of these symptomatic drugs with the aim of providing a sound basis for their clinical use in patients with Alzheimer"s disease. In addition, an introductory chapter considers the basic theory of pharmacology for Alzheimer"s disease and the book closes with an overview of the ways in which symptomatic drugs for dementia are used.The wide acceptance of the amyloid cascade hypothesis has led to vigorous development of disease-modifying drugs for Alzheimer"s disease, such as amyloid vaccinations and gamma- or beta-secretase inhibitors. The failure of clinical trials of these drugs to yield satisfactory results has, however, meant that for the time being patients continue to be treated only with symptomatic drugs. There is accordingly a need to become more proficient in the use of symptomatic medicines, and

it is against the background of this quest that Practical Pharmacology for Alzheimer"s Disease will be of wide interest.

Basic theory of pharmacology for Alzheimer"s disease.- Practical Pharmacology of Donepezil.- Practical pharmacology of Galantamine.- Practical pharmacology of Rivastigmine.- Practical Pharmacology of Memantine.- How do we use Symptomatic drugs for Dementia._

Recenzijos

Written by four experts in dementia research, this book describes the pharmacology of the four symptomatic drugs used in the treatment of Alzheimer's disease. It provides an overview of the basic theories of the pharmacology of Alzheimer's disease and the way in which the medications are used for the treatment of dementia. book is most suitable for geriatric psychiatrists, geriatric medicine specialists, and neurologists who spend a significant amount of time treating people with Alzheimer's disease and other dementias. (Danielle L. Anderson, Doody's Book Reviews, June, 2016)

1 Basic Theory of Pharmacology for Alzheimer's Disease
1(26)
Takashi Kudo
1.1 From the First Report of Alzheimer's Disease to Its Establishment as a Concept
1(3)
1.2 Elucidating the Formation of Neurofibrillary Changes
4(1)
1.3 The Acetylcholine Hypothesis
5(1)
1.4 The Amyloid Hypothesis
6(3)
1.5 Development of Disease-Modifying Drugs (DMDs) Based on the Amyloid Hypothesis
9(4)
1.5.1 Amyloid Vaccination
9(1)
1.5.2 α/β-Secretase Inhibitors
9(4)
1.6 Paradigm Shift of the Dementia Pathology Hypothesis
13(14)
1.6.1 The Pathology of Abnormal Protein Accumulation Commonly Seen in Dementia
13(3)
1.6.2 Endoplasmic Reticulum (ER) Stress and Dementia
16(6)
References
22(5)
2 The Practical Pharmacology of Donepezil
27(8)
Takashi Kudo
2.1 Introduction
27(2)
2.1.1 ACh and Donepezil
28(1)
2.2 Effects Against AD
29(1)
2.2.1 Effects on Cardinal Symptoms in Mild to Moderate AD
29(1)
2.2.2 Effects on Cardinal Symptoms in Advanced AD
29(1)
2.2.3 Effects on the Biological and Psychological Symptoms of Dementia (BPSD) and on Caretaker Burden
29(1)
2.2.4 Effects on Slowing Disease Progression
30(1)
2.3 Effects Against Vascular Dementia
30(1)
2.4 Effects Against Dementia with Lewy Bodies
31(1)
2.4.1 Intracerebral ACh Nerves
31(1)
2.4.2 Donepezil Effects Against DLB
31(1)
2.5 Clinical Use
32(3)
References
32(3)
3 Galantamine for Alzheimer's Disease and Alzheimer's Disease with Cerebrovascular Disease
35(28)
Kenneth L. Davis
3.1 Introduction
35(1)
3.2 Nicotinic Enhancement
35(5)
3.2.1 Peripheral Cholinergic Effects
36(1)
3.2.2 Cognitive Profile
36(1)
3.2.3 Neuroprotection
37(2)
3.2.4 Aβ Clearance
39(1)
3.3 Human Clinical Data
40(23)
3.3.1 Biomarkers
40(3)
3.3.2 Mortality
43(2)
3.3.3 Cognitive and Functional Outcomes
45(2)
3.3.4 Galantamine and Memantine
47(1)
3.3.5 Sleep Disturbance
48(2)
3.3.6 Cholinesterase Inhibitor Withdrawal
50(3)
3.3.7 Tau
53(1)
3.3.8 Long-Term Outcomes in MCI
54(1)
3.3.9 Switch Studies
55(2)
References
57(6)
4 Practical Pharmacology of Rivastigmine
63(42)
Rafael Blesa Gonzalez
Ignacio Flores
Roser Ribosa-Nogue
4.1 Alzheimer's Definition and Treatment Lines
63(1)
4.2 Biochemical and Physiological Aspects of Acetylcholine
64(3)
4.2.1 Introduction
64(1)
4.2.2 Acetylcholine Synthesis and Mechanism of Action
64(1)
4.2.3 Acetylcholine Receptors and Actions
64(1)
4.2.4 Central Nervous System Cholinergic Pathways
65(1)
4.2.5 Functions of Acetylcholine in the Central Nervous System
65(2)
4.2.6 Cholinergic Susceptibility in Aging Brain
67(1)
4.3 Cholinergic Hypothesis in Alzheimer's Disease
67(4)
4.3.1 Loss of Cholinergic Activity
67(1)
4.3.2 Role of Acetylcholine in Learning and Memory
68(1)
4.3.3 Questioning the Cholinergic Hypothesis
69(1)
4.3.4 Corroborating the Cholinergic Hypothesis
70(1)
4.3.5 Reformulating the Cholinergic Hypothesis
71(1)
4.4 The Interplay of Cholinergic Function and Alzheimer's Pathology
71(2)
4.4.1 Cholinergic Agonists and Amyloid Precursor Protein Processing
71(1)
4.4.2 Acetylcholinesterase and Butyrylcholinesterase Relationship with Beta-Amyloid
72(1)
4.4.3 Cholinergic Agonists and Tau Protein
72(1)
4.4.4 Beta-Amyloid and Cholinergic Function
73(1)
4.5 Enhancing Cholinergic Transmission as a Therapy of Alzheimer's Disease
73(1)
4.6 Acetylcholinesterase Inhibitors
74(1)
4.7 Pharmacodynamic Properties of Rivastigmine
75(2)
4.8 Pharmacokinetic Properties of Rivastigmine
77(2)
4.8.1 Absorption and Distribution
77(1)
4.8.2 Metabolism and Elimination
78(1)
4.8.3 Special Populations
79(1)
4.9 Clinical Evidence Supporting the Use of Rivastigmine
79(10)
4.9.1 Cognitive Function
80(2)
4.9.2 Behavioral Symptoms
82(1)
4.9.3 Activities of Daily Living
83(1)
4.9.4 Quality of Life of Patients and Carers
83(1)
4.9.5 Physician-Rated Overall Impression Tests
84(1)
4.9.6 Incidence of Adverse Events
84(5)
4.10 Safety and Tolerability
89(1)
4.10.1 Risk of Overdose and Death
90(1)
4.11 Rivastigmine Efficacy Compared with Other Cholinesterase Inhibitors
90(1)
4.12 Rivastigmine in Clinical Practice
91(1)
4.13 Present and Future of Rivastigmine
92(13)
References
93(12)
5 Practical Pharmacology of Memantine
105(14)
David G. Wilkinson
5.1 Introduction
105(2)
5.1.1 Glutamate and Memantine
105(1)
5.1.2 Effects of Memantine on Neurodegeneration
106(1)
5.2 Memantine in Vascular Dementia
107(1)
5.3 Memantine in AD
108(5)
5.3.1 Clinical Trials
108(1)
5.3.2 Moderately Severe AD
108(2)
5.3.3 Mild to Moderate AD
110(1)
5.3.4 Responder Analyses
111(2)
5.3.5 Safety and Tolerability
113(1)
5.4 Effects of Memantine in Combination with ChEIs
113(1)
5.5 Clinical Use
114(5)
References
116(3)
6 How Do We Use Symptomatic Drugs to Treat Dementia?
119(18)
Takashi Kudo
6.1 Introduction
119(1)
6.2 Characteristics of Symptomatic Drugs
119(6)
6.2.1 Donepezil
119(2)
6.2.2 Galantamine
121(1)
6.2.3 Rivastigmine
122(1)
6.2.4 Memantine
123(2)
6.3 WFSBP Guidelines for the Treatment of Dementia
125(1)
6.3.1 The Preventive Effects of Symptomatic Drugs
125(1)
6.3.2 Indications for Symptomatic Drugs
125(1)
6.3.3 Selection of Drugs and Their Dosage
126(1)
6.3.4 Start and End of Drug Administration and Monitoring
126(1)
6.3.5 Concomitant Therapy
126(1)
6.4 Use of Different Symptomatic Drugs to Suit Different Situations Based on the Guidelines Released by Japan's Six Relevant Academic Societies
126(5)
6.4.1 Guidelines Issued by Japan' Six Relevant Academic Societies
126(1)
6.4.2 Policies on Using Symptomatic Drugs
127(1)
6.4.3 Selection of Drugs
128(3)
6.5 The Overviews of Symptomatic Drugs in AD Drug Guidelines
131(6)
6.5.1 Use of Anti-dementia Drugs to Treat Diseases Other Than AD
131(1)
6.5.2 Future Tasks and Challenges
131(3)
References
134(3)
Index 137
Dr. Takashi Kudo, Osaka University Health Care Center, Department of Psychiatry,Toyonaka, JapanDr. Kenneth Davis, Mount Sinai Medical Center, New York, NY 10029, USADr. Rafael Blesa Gonzalez, Autonomous University of Barcelona, Barcelona, SpainDr. David George Wilkinson, University of Southampton, Southampton, United Kingdom
Daugiau apie elektronines knygas Daugiau apie elektronines knygas
Pastovi nuoroda: https://www.kriso.lt/db/97833192620622e.html
Raktažodžiai: